DexCom, Inc. (DXCM)
NASDAQ: DXCM · Real-Time Price · USD
70.14
+1.49 (2.17%)
At close: Jun 26, 2026, 4:00 PM EDT
69.95
-0.19 (-0.27%)
After-hours: Jun 26, 2026, 7:57 PM EDT
DexCom Revenue
DexCom had revenue of $1.19B in the quarter ending March 31, 2026, with 15.05% growth. This brings the company's revenue in the last twelve months to $4.82B, up 16.15% year-over-year. In the year 2025, DexCom had annual revenue of $4.66B with 15.60% growth.
Revenue (ttm)
$4.82B
Revenue Growth
+16.15%
P/S Ratio
5.62
Revenue / Employee
$434,045
Employees
11,100
Market Cap
27.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.66B | 629.00M | 15.60% |
| Dec 31, 2024 | 4.03B | 410.70M | 11.34% |
| Dec 31, 2023 | 3.62B | 712.50M | 24.49% |
| Dec 31, 2022 | 2.91B | 461.30M | 18.84% |
| Dec 31, 2021 | 2.45B | 521.80M | 27.08% |
| Dec 31, 2020 | 1.93B | 450.70M | 30.54% |
| Dec 31, 2019 | 1.48B | 444.40M | 43.08% |
| Dec 31, 2018 | 1.03B | 313.10M | 43.58% |
| Dec 31, 2017 | 718.50M | 145.20M | 25.33% |
| Dec 31, 2016 | 573.30M | 171.30M | 42.61% |
| Dec 31, 2015 | 402.00M | 142.80M | 55.09% |
| Dec 31, 2014 | 259.20M | 99.20M | 62.00% |
| Dec 31, 2013 | 160.00M | 60.10M | 60.16% |
| Dec 31, 2012 | 99.90M | 23.60M | 30.93% |
| Dec 31, 2011 | 76.30M | 27.70M | 57.00% |
| Dec 31, 2010 | 48.60M | 18.91M | 63.67% |
| Dec 31, 2009 | 29.69M | 19.86M | 201.82% |
| Dec 31, 2008 | 9.84M | 5.21M | 112.62% |
| Dec 31, 2007 | 4.63M | 2.46M | 113.23% |
| Dec 31, 2006 | 2.17M | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GE HealthCare Technologies | 20.98B |
| Boston Scientific | 20.61B |
| Koninklijke Philips | 20.34B |
| Zimmer Biomet Holdings | 8.41B |
| Edwards Lifesciences | 6.30B |
| Smith & Nephew | 6.16B |
| STERIS | 5.94B |
| Bruker | 3.46B |
DXCM News
- 3 days ago - DexCom initiated with a Buy at Deutsche Bank - TheFly
- 3 days ago - DexCom announces milestones to make glucose biosensing more accessible - TheFly
- 3 days ago - DexCom initiated with a Buy at Deutsche Bank - TheFly
- 3 days ago - Dexcom Further Advances Vision of Glucose Biosensing for All - Business Wire
- 8 days ago - Living Longer Is Big Business. These Stocks Will Benefit. - Barrons
- 9 days ago - The Healthcare M&A Wave - Forbes
- 11 days ago - DexCom price target raised to $88 from $75 at Piper Sandler - TheFly
- 14 days ago - FDA clears first over-the-counter glucose monitor for children - Reuters